24/7 Market News Snapshot 20 May, 2025 – bioAffinity Technologies, Inc. Common Stock (NASDAQ:BIAF)

May 20, 2025

DENVER, Colo., 20 May, 2025 (www.247marketnews.com) – (NASDAQ:BIAF) are discussed in this article.
bioAffinity Technologies, Inc. is currently experiencing a notable surge in pre-market trading, with shares reaching $0.282, reflecting a substantial increase of 25.3% from the previous close of $0.225. This uptick is marked by a trading volume of 45.96 million shares, indicating heightened investor interest and confidence in the company’s innovative approach to biotechnology. Analysts suggest that this positive trajectory could signal further upward movement, making bioAffinity a compelling option for investors closely monitoring the market.

In tandem with this financial momentum, bioAffinity Technologies has announced the appointment of Dr. Gordon Downie as its new Chief Medical Officer. Dr. Downie brings over three decades of experience in pulmonary medicine and clinical research, which is anticipated to significantly enhance the company’s efforts in noninvasive cancer diagnostic testing. His extensive background includes numerous peer-reviewed publications centered on bronchoscopy advancements and early lung cancer identification, demonstrating his commitment to improving patient outcomes.

Expressing his enthusiasm, Dr. Downie stated that he is eager to contribute to bioAffinity’s mission, particularly in advancing CyPath® Lung, a groundbreaking diagnostic tool designed to detect malignancy in lung nodules. His leadership is expected to expand awareness and accessibility of this innovative test, which uses advanced flow cytometry and artificial intelligence to analyze sputum samples with remarkable sensitivity and accuracy.

Maria Zannes, the President and CEO of bioAffinity Technologies, highlighted that Dr. Downie’s clinical expertise and passion for early detection align perfectly with the company’s strategic objectives. The bioAffinity team is optimistic about the advancements in cancer diagnostics that will unfold under Dr. Downie’s guidance, marking a significant step forward in their commitment to improving patient care and survival rates in lung cancer diagnosis.

Related news for (BIAF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.